Oct 28, 2019
FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Six Years, the Longest Approved Duration of Use of Any Hormonal IUDs
Oct 21, 2019
Bayer Submits Supplemental New Drug Application to FDA for Intrauterine Device (IUD) Mirena® (levonorgestrel-releasing intrauterine system) 52 mg
Jul 02, 2019
The Future of the Intrauterine Devices (IUD) Market by Product, End-use and Region (2019-2024)
May 06, 2019
Medicines360 and Allergan Present Six-Year Clinical Data from Largest Ongoing Phase 3 Study of an Intrauterine System in the U.S.
Dec 10, 2018
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years
Oct 16, 2018
FDA Approves Medicines360's sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
Sep 06, 2018
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Aug 20, 2018
Medicines360 and Direct Relief Partner to Expand Access for U.S. Women
May 07, 2018
Medicines360, WCG, and Population Services International Announce Launch of AVIBELA(TM) Hormonal Intrauterine System in Madagascar
Apr 30, 2018
Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study
Apr 26, 2018
Allergan to Present New Data at the American College of Obstetrics and Gynecology 67th Annual Clinical and Scientific Meeting 2018
Feb 22, 2018
FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Jan 08, 2018
Global Contraceptive Devices Market Forecast to 2027